The diagnosis of chronic kidney disease (CKD) requires a comprehensive assessment that includes clinical symptom observation, laboratory tests, and imaging techniques. Physicians typically perform a systematic evaluation based on the patient's medical history, severity of symptoms, and risk factors. Early diagnosis can effectively delay disease progression, and thus the medical community has developed various quantitative indicators to monitor renal function status.
The diagnostic process is generally divided into three stages: initial screening, detailed assessment, and differential diagnosis. Physicians first evaluate overall kidney function using basic indicators such as serum creatinine and urine protein levels. Further examinations may include renal ultrasound, renal biochemical analysis, and even renal biopsy to confirm tissue changes. This layered approach helps precisely determine the disease stage and underlying cause.
Clinical assessment is the foundation of diagnosis. Physicians will inquire in detail about the patient's past medical history and medication use. The presence of complications such as hypertension, diabetes, and cardiovascular disease often indicates long-term kidney damage. Patients who have undergone contrast imaging or used nephrotoxic drugs should also be noted during evaluation.
Symptom assessment includes common warning signs such as swelling, changes in urine (e.g., foamy urine or hematuria), fatigue, and loss of appetite. Physicians will pay attention to the duration and severity of symptoms and evaluate whether there are other systemic abnormalities, such as bone lesions or metabolic disturbances.
Physical examination focuses on edema, blood pressure abnormalities, and neurological signs. Lower limb edema may reflect impaired renal excretion, while persistent hypertension can exacerbate kidney damage. These clinical findings will be cross-referenced with laboratory data to confirm the diagnostic direction.
Blood tests are key tools for assessing kidney function, with main indicators including:
Urinalysis includes 24-hour urine protein quantification to accurately measure the extent of filtration barrier damage. Urinary sediment analysis can observe the number of red blood cells, white blood cells, and casts, aiding in distinguishing primary renal diseases from systemic disease effects. Special indicators such as the Albumin/Creatinine Ratio (ACR) have become standard screening tools for CKD.
Imaging examinations include:
Invasive procedures like renal biopsy are usually performed when the cause of kidney dysfunction is unclear or to differentiate types of glomerular diseases. This procedure allows direct observation of pathological changes in kidney tissue but requires careful consideration of its necessity and risks.
Screening for CKD mainly involves two core indicators: estimated Glomerular Filtration Rate (eGFR) and urine albumin excretion. eGFR is calculated based on age, sex, and serum creatinine levels, with normal values typically between 60-120 mL/min/1.73m². An eGFR below 60 for more than three months, combined with abnormal urine findings, confirms the diagnosis.
Urinalysis tools include the Albumin/Creatinine Ratio (ACR), which effectively screens for microalbuminuria. A normal ACR should be less than 30 mg/g; exceeding this indicates proteinuria. Physicians may recommend annual testing for high-risk groups such as diabetics.
Risk assessment tools include models predicting CKD progression risk, integrating data such as age, blood pressure, and lipid levels to estimate disease worsening probability. These tools assist physicians in developing personalized follow-up plans, such as recommending biannual kidney function screening for certain populations.
Differential diagnosis involves ruling out acute kidney injury, urinary obstruction, and metabolic diseases. For example, patients with acute renal failure may experience a rapid decline in eGFR within weeks, whereas chronic disease shows a slow progressive change. Blood tests measuring BUN and serum creatinine ratios, along with imaging, help confirm changes in kidney size.
Systemic diseases that need to be distinguished from primary renal diseases include diabetic nephropathy, lupus nephritis, and multiple myeloma-related kidney damage. Diabetic patients with proteinuria should undergo further renal biochemical analysis to confirm glomerular filtration impairment. Patients with autoimmune diseases should be tested for autoantibodies such as ANA.
Medication effects, such as NSAID-induced nephropathy, should also be considered. Physicians will inquire about medication history and compare kidney function indicators before and after discontinuation.
Early diagnosis can delay progression to end-stage renal failure. When the glomerular filtration rate (eGFR) is still within the normal range, the presence of microalbuminuria indicates damage to the glomerular barrier. Interventions at this stage can significantly reduce the risk of progression by 50%.
Early detection allows for controlling comorbidities, such as using antihypertensive drugs to reduce proteinuria or SGLT2 inhibitors to slow renal decline. Studies show that early use of ACE inhibitors can reduce the rate of kidney function deterioration by over 30%.
Regular screening helps track disease trajectory. It is recommended that high-risk groups undergo eGFR and ACR testing every 6-12 months, with treatment strategies adjusted based on changes in these indicators. This proactive management can improve overall prognosis and quality of life for patients.
CKD often has no obvious symptoms in its early stages, so regular blood and urine tests are crucial. Physicians evaluate kidney function through eGFR and ACR, which help detect abnormalities before symptoms appear, allowing for early intervention.
What role do imaging tests play in diagnosing CKD?Ultrasound can observe kidney shape, size, and structural abnormalities such as shrinkage or stones, helping to exclude other diseases and assess the extent of kidney damage. In complex cases, further use of CT or angiography may be necessary for precise evaluation of blood flow and tissue changes.
Can lifestyle modifications delay the diagnosis of CKD?Incorrect. The correct approach involves healthy eating (such as low salt and low protein diets), blood pressure and blood sugar control to slow disease progression, not delaying diagnosis. If kidney function abnormalities are present, early medical consultation and treatment planning are essential; lifestyle alone cannot replace medical management.
Why do some people have CKD without obvious symptoms?Early CKD often remains asymptomatic due to compensatory renal function. Symptoms like fatigue and edema usually appear only after more than 50% of kidney function is lost. Therefore, high-risk groups (such as diabetics and hypertensives) should undergo screening every six months to avoid delayed diagnosis.
Why is regular monitoring of kidney function indicators necessary after diagnosis?Monitoring eGFR and urine protein helps assess disease progression and treatment effectiveness, as well as early detection of complications such as anemia or metabolic disturbances. Physicians adjust medications and treatment plans based on these data to reduce risks of uremia and cardiovascular disease.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
